Pro 2014-008 (Announcement of Jianfeng Group on Cancellation of Subsidiary)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2014-008
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Cancellation of Subsidiary
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
1. Overview
Company At the 14th meeting of the 8th Board of Directors held on April 11, 2014, the "Proposal on Cancellation of Zhejiang Jinhua Zhongneng Products Co., Ltd." The voting result: 9 votes in favor, 0 votes against, and 0 abstentions.
Basic Information of 2. Zhongneng Products
Zhejiang Jinhua Zhongneng Products Co., Ltd. (hereinafter referred to as Zhongneng Products ) is a wholly-owned subsidiary of the company's holding subsidiary Zhejiang Jianfeng International Trade Co., Ltd. (hereinafter referred to as Jianfeng International Trade Co., Ltd. ), which was established on December 24, 2012, the company has a registered capital of 10 million yuan and was registered and established in Wucheng Branch of Jinhua Administration for Industry and Commerce. Its domicile is 88 Wujiang East Road, Jinhua City, and its business license registration number is 330702000076017.
Business Scope: Purchase and sales of chemical raw materials and products, pharmaceutical intermediates (except hazardous chemicals, precursor chemicals, monitoring chemicals); procurement and sales of rubber, Wujinjiaodian, daily necessities, wood pulp, paper, steel, non-ferrous metal materials, textiles, clothing, primary edible agricultural products, handicrafts (except cultural relics), building decoration materials, mechanical equipment, instruments and meters, packaging materials, communication cables and equipment (except radio); logistics supply chain consulting services; Business consulting service activities permitted by national laws and policies; domestic and international freight forwarding business. (The above business scope does not include projects prohibited, restricted and permitted by national laws.)
In 2013, Zhongneng Products realized operating income of 87.9136 million yuan and net profit of -106200 yuan. By the end of 2013, total assets were 10.3488 million yuan, net assets were 9.7963 million yuan and liabilities were 552500 yuan.
3. The main business activity of Zhongneng Products
Zhongneng Products is the spot trade of PVC, and PVC is a mature chemical product. Large-scale PVC traders use the combination of futures and spot. In addition, for some relatively large-scale and well-known PCV production enterprises, there are basically long-term cooperative agents in East China. Zhongneng products can only obtain the source of goods through agents. The purchase price is relatively high and there is no advantage in the competition.
Impact of 4. on the Company
According to the operation of Zhongneng Products, the Board of Directors believes that its PVC trading business has no obvious advantages and is difficult to become bigger and stronger. According to the company's implementation of flat control mode, reduce the subsidiary management level, reduce the management cost requirements. The Board of Directors made a resolution to cancel the company, and the assets and related business of Zhongneng Property were undertaken by its parent company, Peak International Trade. The existing assets of Zhongneng Property are in clear condition, the proportion of its business income to the company's overall operating income is not high, the profit and loss is small, the cancellation of Zhongneng Property will not have a significant impact on the company's overall assets and profitability.
The independent directors of the company issued an independent opinion for this, and believed that the formation of the resolution complied with the "Company Law", the company's "Articles of Association" and other relevant regulations, and did not harm the interests of small and medium shareholders.
5. Reference Document
Resolution of the 14th Meeting of the 8th Board of Directors of the Company;
hereby announces
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
April 15, 2014
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11